Sign in

Acute myeloid leukaemia: trials that stopped early

Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

    Reason given in the registry

    “The study was closed due to the end of funding.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Aug 2026.

    Ended
    Jul 2026
    Phase
    Phase 2
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT04994808
  2. Withdrawn

    A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

    Reason given in the registry

    “Lack of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Aug 2026.

    Phase
    Phase 2
    Run by
    Memorial Sloan Kettering Cancer Center
    Registry record
    NCT06903702
  3. Terminated

    A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

    Reason given in the registry

    “Slow participant enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Jul 2026.

    Ended
    Mar 2026
    Phase
    Phase 1
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06021600
  4. Suspended

    Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

    Reason given in the registry

    “Drugs/Equipment Unavailable”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Jul 2026.

    Phase
    Phase 1
    Run by
    Washington University School of Medicine
    Registry record
    NCT05377827
  5. Suspended

    Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

    Reason given in the registry

    “Drugs unavailable”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2026.

    Phase
    Phase 1
    Run by
    David Wald
    Registry record
    NCT05400122
  6. Terminated

    Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

    Reason given in the registry

    “Funding Sponsor decision due to review of efficacy data from other trials involving investigational product.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Jul 2026.

    Ended
    Jun 2026
    Phase
    Phase 1
    Run by
    Antonio M Jimenez Jimenez
    Registry record
    NCT06158100
  7. Terminated

    Lentivirally Redirected CD123 Autologous T Cells in AML

    Reason given in the registry

    “Administrative reasons.”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2026.

    Ended
    Mar 2026
    Phase
    Phase 1
    Run by
    University of Pennsylvania
    Registry record
    NCT03766126
  8. Withdrawn

    ENLIGHT-AML - An Open-label, Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Study withdrawn due to business priority changes”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Jul 2026.

    Phase
    Phase 1
    Run by
    Galecto Biotech AB
    Registry record
    NCT07084584
  9. Terminated

    Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

    Reason given in the registry

    “Upon analysis of the first 7 participants accrued, it was determined that this combination treatment is not efficacious as treatment for patients with relapsed or refractory AML”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Jun 2026.

    Ended
    Jul 2025
    Phase
    Phase 1
    Run by
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Registry record
    NCT05716009
  10. Terminated

    Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)

    Reason given in the registry

    “Premature withdrawal of investigational product per study sponsor.”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Jun 2026.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Northwestern University
    Registry record
    NCT05744739
  11. Terminated

    A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Sponsor's decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Jun 2026.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    Sanofi
    Registry record
    NCT05712278
  12. Terminated

    Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

    Reason given in the registry

    “The study was stopped due to exhaustion of funding. No additional financial support could be obtained to continue study operations as planned.”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Jun 2026.

    Ended
    Dec 2025
    Run by
    Center for International Blood and Marrow Transplant Research
    Registry record
    NCT05224661
  13. Withdrawn

    γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant

    Reason given in the registry

    “Due to corporate strategic adjustment.”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2026.

    Phase
    Early phase 1
    Run by
    Guangzhou Bio-gene Technology Co., Ltd
    Registry record
    NCT07123662
  14. Terminated

    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

    Reason given in the registry

    “No longer a research question to answer.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2026.

    Ended
    May 2026
    Run by
    Masonic Cancer Center, University of Minnesota
    Registry record
    NCT01962636
  15. Terminated

    Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

    Reason given in the registry

    “Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 May 2026.

    Ended
    May 2025
    Phase
    Phase 2
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT03246906
  16. Withdrawn

    A Study of c-Kit Mutation as MRD in Acute Myeloid Leukemia

    Reason given in the registry

    “The test for c-kit was not set up and replaced by NGS MRD”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 May 2026.

    Ended
    Nov 2026
    Run by
    Institute of Hematology & Blood Diseases Hospital, China
    Registry record
    NCT06116318
  17. Terminated

    Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

    Reason given in the registry

    “Closed for administrative, non-safety-related reasons.”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 May 2026.

    Ended
    Jan 2025
    Phase
    Phase 1/2
    Run by
    Sun Pharma Advanced Research Company Limited
    Registry record
    NCT02629692
  18. Withdrawn

    A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

    Reason given in the registry

    “Other - Protocol moved to Withdrawn”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 May 2026.

    Phase
    Phase 1
    Run by
    Children's Oncology Group
    Registry record
    NCT07498465
  19. Terminated

    Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

    Reason given in the registry

    “The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice daily), but was closed early due to slow enrollment and changing treatment landscape moving towards less intense approaches.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Apr 2026.

    Ended
    Feb 2025
    Phase
    Phase 1/2
    Run by
    Ohio State University Comprehensive Cancer Center
    Registry record
    NCT03878199
  20. Terminated

    Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

    Reason given in the registry

    “75% \> Participants”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2026.

    Ended
    Mar 2025
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04435691
  21. Terminated

    A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

    Reason given in the registry

    “Patient recruitment problems.”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Apr 2026.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Aurigene Discovery Technologies Limited
    Registry record
    NCT05607199
  22. Terminated

    Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    Reason given in the registry

    “Adjusted the product development strategy.”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2026.

    Ended
    Dec 2024
    Phase
    Phase 1
    Run by
    Changchun GeneScience Pharmaceutical Co., Ltd.
    Registry record
    NCT05263271
  23. Suspended

    Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

    Reason given in the registry

    “Enrollment on hold pending amendment”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.

    Phase
    Phase 1
    Run by
    University of Chicago
    Registry record
    NCT02333162
  24. Terminated

    A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

    Reason given in the registry

    “Slow/low Enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Mar 2026.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Inmune Bio, Inc.
    Registry record
    NCT05933070
  25. Terminated

    Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

    Reason given in the registry

    “Development discontinued”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Mar 2026.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    Shattuck Labs, Inc.
    Registry record
    NCT05275439
  26. Terminated

    A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

    Reason given in the registry

    “Business reasons, not related to safety or efficacy results.”

    Quoted unchanged from ClinicalTrials.gov; record updated 17 Mar 2026.

    Ended
    Jul 2024
    Phase
    Phase 1
    Run by
    MEI Pharma, Inc.
    Registry record
    NCT03547115
  27. Terminated

    Natural Killer-cell Therapy for Acute Myeloid Leukemia

    Reason given in the registry

    “Stop funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Mar 2026.

    Ended
    Jan 2026
    Phase
    Phase 1/2
    Run by
    Radboud University Medical Center
    Registry record
    NCT04347616
  28. Suspended

    2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

    Reason given in the registry

    “Pharmaceutical Company withdrew support and investigational product”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2026.

    Phase
    Phase 1
    Run by
    University of Maryland, Baltimore
    Registry record
    NCT06626633
  29. Terminated

    Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

    Reason given in the registry

    “\<75% participation”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Mar 2026.

    Ended
    Mar 2026
    Phase
    Phase 2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT03404193
  30. Terminated

    Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Reason given in the registry

    “Drug supply issues”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Mar 2026.

    Ended
    May 2025
    Phase
    Phase 1
    Run by
    National Cancer Institute (NCI)
    Registry record
    NCT03772925

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.